This study demonstrates the molecular docking of Kanglixin capsules, revealing 187 targets in non-small cell lung cancer, suggesting therapeutic pathways.
Key Points
Molecular docking revealed that active compounds in Kanglixin capsules effectively bind to non-small cell lung cancer targets, enhancing therapeutic potential.
A total of 688 gene targets related to non-small cell lung cancer were identified, along with 187 overlapping targets with Kanglixin capsules' active compounds.
Network pharmacology analysis identified critical pathways, including the non-small cell lung cancer pathway, and highlighted the complex interactions of active compounds.
Gene ontology analysis revealed over 1145 entries detailing the functional roles of the involved gene targets, supporting their significance in treatment strategies.